ClinicaliQ Trial Snapshot
- CHAMPION-AF Clinical Trial — Active Not Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT04394546.
- WATCHMAN FLX device closure of the heart's left atrial appendage works as well as anticoagulant tablets for stroke prevention in atrial fibrillation.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation. Conditions: Atrial Fibrillation, Stroke, Bleeding Interventions: WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant Lead Sponsor: Boston Scientific Corporation Planned Enrollment: 3000 participants